Matches in SemOpenAlex for { <https://semopenalex.org/work/W1775621567> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W1775621567 endingPage "681" @default.
- W1775621567 startingPage "681" @default.
- W1775621567 abstract "Back to table of contents Previous article Next article Letters to the EditorFull AccessDr. McGrath Replies on Behalf of the STAR*D Trial TeamSTAR*D Trial TeamSTAR*D Trial TeamSearch for more papers by this authorPublished Online:1 Apr 2007AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Drs. Wingo and Ghaemi raise two methodological points regarding our article describing the results from Level 4 treatment in the STAR*D. The first point is that adjusting for previous medication intolerance, which differed between the tranylcypromine and venlafaxine/mirtazapine groups, would be important to estimate comparative effects of the treatments. We agree, and in fact did adjust for this in the analyses we presented, as is noted in footnote b to Table 3.The second point suggests that we downplayed a numerical difference in the response rate between the two treatments that was not statistically significant, essentially endorsing a lack of difference in treatments possibly because of a type II error. Drs. Wingo and Ghaemi are correct that our primary endpoint of remission had limited power to detect small effect sizes. However, we chose to emphasize the primary endpoint of remission because it was specified a priori, which limits the possibility of chance findings to the specified significance rate, which is not the case if multiple outcome measures are analyzed separately. They assert that the nonsignificant difference on the secondary measure of response is “most consistent with a high probability of an effect.” We disagree—the probability of an effect in this data is clearly not “high” because the probability is most correctly described by the probability of a type I error, that is, the p value. Whether a larger study might find these numerical differences to be significantly different remains speculative.We believe that Drs. Wingo and Ghaemi neglect another more likely explanation of any putative difference between treatments, which is that poorer tolerability of tranylcypromine in this study resulted in shorter durations of treatment and less chance to show improvement. However, even accepting their interpretation of the response rates leads to the same conclusion stated in our article, perhaps with the addition noted in brackets: “The lower side effect burden, lack of dietary restrictions, [numerical though not significant advantage in response rate], and ease of use of venlafaxine and mirtazapine suggest that this combination may be preferred over tranylcypromine for patients with highly-resistant depression who have not benefited adequately from several prior treatments.”Author disclosures accompany the original article. FiguresReferencesCited byDetailsCited ByNone Volume 164Issue 4 April, 2007Pages 681-681THE AMERICAN JOURNAL OF PSYCHIATRY April 2007 Volume 164 Number 4 Metrics PDF download History Published online 1 April 2007 Published in print 1 April 2007" @default.
- W1775621567 created "2016-06-24" @default.
- W1775621567 creator A5053077350 @default.
- W1775621567 date "2007-04-01" @default.
- W1775621567 modified "2023-10-18" @default.
- W1775621567 title "Dr. McGrath Replies on Behalf of the STAR*D Trial Team" @default.
- W1775621567 doi "https://doi.org/10.1176/appi.ajp.164.4.681-a" @default.
- W1775621567 hasPublicationYear "2007" @default.
- W1775621567 type Work @default.
- W1775621567 sameAs 1775621567 @default.
- W1775621567 citedByCount "0" @default.
- W1775621567 crossrefType "journal-article" @default.
- W1775621567 hasAuthorship W1775621567A5053077350 @default.
- W1775621567 hasConcept C105795698 @default.
- W1775621567 hasConcept C126322002 @default.
- W1775621567 hasConcept C134306372 @default.
- W1775621567 hasConcept C15744967 @default.
- W1775621567 hasConcept C168563851 @default.
- W1775621567 hasConcept C203092338 @default.
- W1775621567 hasConcept C2524010 @default.
- W1775621567 hasConcept C2780897414 @default.
- W1775621567 hasConcept C28719098 @default.
- W1775621567 hasConcept C33923547 @default.
- W1775621567 hasConcept C40696583 @default.
- W1775621567 hasConcept C70410870 @default.
- W1775621567 hasConcept C71924100 @default.
- W1775621567 hasConceptScore W1775621567C105795698 @default.
- W1775621567 hasConceptScore W1775621567C126322002 @default.
- W1775621567 hasConceptScore W1775621567C134306372 @default.
- W1775621567 hasConceptScore W1775621567C15744967 @default.
- W1775621567 hasConceptScore W1775621567C168563851 @default.
- W1775621567 hasConceptScore W1775621567C203092338 @default.
- W1775621567 hasConceptScore W1775621567C2524010 @default.
- W1775621567 hasConceptScore W1775621567C2780897414 @default.
- W1775621567 hasConceptScore W1775621567C28719098 @default.
- W1775621567 hasConceptScore W1775621567C33923547 @default.
- W1775621567 hasConceptScore W1775621567C40696583 @default.
- W1775621567 hasConceptScore W1775621567C70410870 @default.
- W1775621567 hasConceptScore W1775621567C71924100 @default.
- W1775621567 hasIssue "4" @default.
- W1775621567 hasLocation W17756215671 @default.
- W1775621567 hasOpenAccess W1775621567 @default.
- W1775621567 hasPrimaryLocation W17756215671 @default.
- W1775621567 hasRelatedWork W164715714 @default.
- W1775621567 hasRelatedWork W1988395127 @default.
- W1775621567 hasRelatedWork W2077607936 @default.
- W1775621567 hasRelatedWork W2152605104 @default.
- W1775621567 hasRelatedWork W2302405038 @default.
- W1775621567 hasRelatedWork W2748952813 @default.
- W1775621567 hasRelatedWork W2899084033 @default.
- W1775621567 hasRelatedWork W3007549562 @default.
- W1775621567 hasRelatedWork W4205858822 @default.
- W1775621567 hasRelatedWork W4318664217 @default.
- W1775621567 hasVolume "164" @default.
- W1775621567 isParatext "false" @default.
- W1775621567 isRetracted "false" @default.
- W1775621567 magId "1775621567" @default.
- W1775621567 workType "article" @default.